01-12-2023 | Thrombocytopenia | Case report
Ipilimumab/Nivolumab/Pembrolizumab
Pure red cell aplasia, bell's palsy and immune thrombocytopenia
Published in: Reactions Weekly | Issue 1/2023
Login to get accessExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event